Article
NUDT15 is a key genetic factor for prediction of hematotoxicity in pediatric patients who received a standard low dosage regimen of 6-mercaptopurine.
Drug metabolism and pharmacokinetics - 1 Apr 2022
Khaeso Kanyarat, Komvilaisak Patcharee, Chainansamit Su-On, Nakkam Nontaya, Suwannaying Kunanya, Kuwatjanakul Pitchayanan, Hikino Keiko, Dornsena Areerat, Kanjanawart Sirimas, Laoaroon Napat, Vannaprasaht Suda, Taketani Takeshi, Tassaneeyakul Wichittra
Abstract excerpt
6-Mercaptopurine (6-MP) is commonly used for treatment of acute lymphoblastic leukemia (ALL). The incidence of hematotoxicity caused by this drug is quite high in Asians even using a standard low dosage regimen. The present study was aimed to elucidate the impact of thiopurine S-methyltransferase (TPMT), a nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15), inosine triphosphatase (ITPA) and ATP Binding...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.